

Management Certification

The undersigned, on behalf of Retrieve Medical Holdings, Inc. ("the Company"), certifies that the information provided herein is accurate and complete to the best of the Company's knowledge.

1. The Company is current in its disclosure obligations pursuant to the following reporting standard:

SEC Reporting Obligations

- The Company has a reporting obligation under Section 13 or 15(d) of the Exchange Act
- The Company has a reporting obligation under Regulation A (Tier 2)
- The Company has a reporting obligation under Regulation Crowdfunding (CF)

--	--

Other Reporting Obligations

- The Company is a U.S. bank, bank holding company, or similar financial institution exempt from SEC registration, has a reporting obligation to a U.S. Bank Regulator and follows OTC Markets' Bank Reporting requirements.
- The Company is exempt from SEC registration and is reporting under the Alternative Reporting Standard

2. Indicate below whether the Company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

3. Indicate below whether the Company is subject to Bankruptcy or reorganization proceedings.

Yes: No:

4. The Company has a Verified Company Profile on OTCMarkets.com.
5. The Company is duly organized and in good standing under the laws of the state or jurisdiction in which the Company is organized or does business.
6. The Company understands and acknowledges its obligations to report company-related actions pursuant to Exchange Act Rule 10b-17 and FINRA Rule 6490.
7. The Company understands and acknowledges its obligations to publicly disclose material information in a timely manner in accordance with applicable U.S. federal securities laws, including but not limited to Section 10(b) of the Exchange Act and Rule 10b-5 thereunder.
8. The Company's transfer agent and its address are listed below. If the Company acts as its own transfer agent, indicate that by listing the Company and its information in the fields provided.¹

Transfer Agent: Securities Transfer Corporation

Address: 2901 Dallas Parkway, Suite 380, Plano TX 75093

¹ OTCQX, OTCQB, and OTCID companies are required to retain a transfer agent that participates in the Transfer Agent Verified Shares Program. OTCID companies that act as their own transfer agent may submit data directly to OTC Markets.

9. The Company's most recent Annual Report was prepared by:

Below is a list all law firm(s) and attorney(s) (including internal counsel) that acted as the Company's primary legal counsel in preparing its most recent annual report or, if no attorney assisted in preparing the disclosure, the person(s) who prepared the disclosure and their relationship to the Company.

Securities Counsel

Name: Lawrence Metelitsa, Partner
 Firm: Lucosky Brookman LLP
 Address 1: 101 Wood Avenue South
 Address 2: Woodbridge, NJ 08830
 Phone: (732) 395 4405
 Email: lmelitsa@lucbro.com

Accountant or Auditor

Name: Jeorg Klaube, CFO
 Firm: Retrieve Medical Holdings, Inc.
 Address 1: 376 Main Street, Suite 100
 Address 2: Bedminster, NJ 07921
 Phone: 908) 510-3247
 Email: jklaube@retrievemedical.com

10. The Company's Officers, Directors and 5% Beneficial Owners are listed below:

The table below provides information regarding all officers and directors of the Company, or any person that performs a similar function, regardless of the number of shares they own. To the best of the Company's knowledge, it includes all individuals or entities beneficially owning 5% or more of any class of the issuer's equity securities. To identify holders of 5% or more, companies may obtain a recent copy of their shareholder list that includes Non-Objecting Beneficial Owners or "NOBOs." SEC Reporting companies may also research their beneficial ownership and insider transaction filings such as on Schedules 13G or 13D or on Forms 3, 4, and 5.

As of (latest practicable date): April 13, 2026

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, ≥ 5% beneficial owner)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
Jerry Swon	Chief Executive Officer/Director	Mendham, NJ	2,783,797	Common	9.96%
Joerg Klaube	Chief Financial Officer	Brick, NJ	705,008	Common	2.52%
Mark Rosenberg	Director	Denville, NJ	1,427,704	Common	5.11%
Jason Pottinger	Director	Oakville, ON Can	335,535	Common	1.20%
Todd Griffith	Director	Valley, NE	1,068,918	Common	3.82%
Louis C. Rose	Director	New York, NY	862,485	Common	3.09%
Academic Innovation Partners Inc.	Affiliate	Fountain, CO	1,007,896	Common	3.61%

Richard Perlman	Affiliate	Chicago, IL	2,747,545	Common	9.83%
-----------------	-----------	-------------	-----------	--------	-------

Any additional material details, including conversion terms of any class of the issuer's equity securities, are below:

N/A

11. The Company has Convertible Debt as detailed below:

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ²	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)
3/21/2017	10,000	10,000	3/21/2018	Convertible into Common Stock ⁽¹⁾⁽³⁾	-0-	17,241	Trius Holdings Limited ⁽⁵⁾	Working Capital
1/10/2018	23,000	23,000	7/9/2018	Promissory Note ⁽²⁾⁽³⁾	-0-	-0-	Mediapark Investments Limited ⁽⁴⁾	Working Capital
1/21/2020	100,000	100,000	1/15/2021	Convertible into Common Stock ⁽⁶⁾⁽³⁾	-0-	56,400	Richard M. Perlman	Working Capital
10/2/2020	100,000	100,000	10/2/2021	Convertible into Common Stock ⁽³⁾⁽⁶⁾	-0-	56,400	Richard M. Perlman	Working Capital
3/31/2023	100,000	100,000	6/30/2023	Convertible into Common Stock ⁽⁶⁾⁽³⁾	-0-	56,400	Richard M. Perlman	Working Capital
9/3/2023	20,000	20,000	10/9/2023	Convertible into Common Stock ⁽⁶⁾⁽³⁾	-0-	20,000	Richard M. Perlman	Working Capital

² The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

9/14/2023	17,500	17,500	11/14/23	Promissory Note ^{(2) (3)}	-0-	-0-	Jacob Agai	Working Capital
9/14/2023	7,500	7,500	11/14/23	Promissory Note ^{(2) (3)}	-0-	-0-	Robert S. Barnett	Working Capital
9/26/2023	25,000	25,000	10/26/23	Promissory Note ^{(2) (3)}	-0-	-0-	Dennis Hall	Working Capital
10/17/23	25,000	25,000	4/17/2024	Promissory Note ^{(2) (3)}	-0-	-0-	James Noonan	Working Capital
1/8/2024	10,000	10,000	On Demand	Promissory Note ⁽²⁾	-0-	-0-	Todd Griffith	Working Capital
1/18/2024	5,000	-0-	On Demand	Promissory Note ⁽²⁾	-0-	-0-	Jay Lankford	Working Capital
2/7/2024	10,000	10,000	4/30/2024	Promissory Note ^{(2) (3)}	-0-	-0-	Robert Dash	Working Capital
2/26/2024	100,000	-0-	On Demand	Promissory Note ⁽²⁾	-0-	-0-	Louis Rose	Working Capital

Total Outstanding Balance: \$448,000

Total Shares: 0 206,441

Any additional material details, including footnotes to the table are below :

- (1) Convertible at any time at a conversion price of 20% discount to the closing price of the common stock on the date of the Lender's notice of conversion, subject to a floor of \$0.01.
- (2) This note is not convertible into common stock.
- (3) Each of the notes are in technical default. The Company has not extended any of the due dates as of the date of this report.
- (4) Mediapark Investments Limited is controlled by Rami Sakka.
- (5) Trius Holdings Limited is controlled by Rami Sakka.
- (6) Convertible at any time at a conversion price of \$1.00 per share.

Signature:

Name of Principal Executive Officer or Principal Financial Officer: Joerg Klaube

Title: Chief Financial Officer

Date: April 15, 2026

Signature: /s/ Joerg Klaube